The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker.Two additional scientific abstracts from the NATIVE Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH have been selected for presentation. The two abstracts show: the correlation between the increase of adiponectin under lanifibranor and the improvement of histological and serum markers of NASH severity both in terms of activity and
BOSTON (BUSINESS WIRE) #TLM22 PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, today announced that the organization’s recent research will be presented at the upcoming 2022 AASLD 2022 Liver Meeting , which will be held in Washington, D.C. from November 4-8, 2022. At this.
In a new study conducted by Tracey G. Simon and colleagues, it was noted that Swedish children and young adults with biopsy-confirmed non-alcoholic fatty liver disease (NAFLD) have significantly.
Frontiers | Expression of MICA in Zero Hour Biopsies Predicts Graft Survival After Liver Transplantation frontiersin.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from frontiersin.org Daily Mail and Mail on Sunday newspapers.